Research institution
Masonic Cancer Center, University of Minnesota Clinical Trials
Studies where Masonic Cancer Center, University of Minnesota is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 35Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Auto Stem Cell Transplant for Lymphoma Patients
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.
- Trial name
- NCT03125642
- Testing
- Etoposide, BCNU, AraC
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Prostate Carcinoma
Evaluating Prostate Cancer Patient Natural Killer Cell Function Across Racial Background and Addressing Functional Disparities With Trispecific Killer Engagers
This study collects, stores and analyzes blood specimens and information from people with prostate cancer. This may help researchers understand whether certain white blood cells involved in immunity differs between prostate…
- Trial name
- NCT07910019
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Neuroblastoma
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
This is a phase II single center study to administer two courses of myeloablative consolidation chemotherapy each followed by an autologous peripheral blood stem cell (PBSC) rescue in patients with high-risk neuroblastoma who…
- Trial name
- NCT02605421
- Testing
- Thiotepa, Cyclophosphamide, Melphalan
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia, TP53
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
This is a Phase I/II study evaluating safety and efficacy of proteasome inhibitor (bortezomib) in combination with CPX-351 (liposomal daunorubicin and cytarabine) for the treatment of newly-diagnosed TP53-mutated acute myeloid…
- Trial name
- NCT07008638
- Testing
- Bortezomib, CPX-351
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lymphatic Diseases, Hematopoietic Malignancy
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
For the next 5-10 years or possibly longer, a high proportion of the Cord Blood Banks (CBB) inventory worldwide will be composed of unlicensed umbilical cord blood (UCB) units.
- Trial name
- NCT01451502
- Testing
- Umbilical Cord Blood (UCB)
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Autologous Stem Cell Transplant, Classic Hodgkin Lymphoma
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
This is a Phase 2 single arm study to evaluate efficacy and safety of Pembrolizumab before with BEAM ASCT followed by Pembrolizumab maintenance for 1 year.
- Trial name
- NCT06377540
- Testing
- Pembrolizumab, Autologous stem cell transplant, Carmustine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Adenocarcinoma of Lung, Lung Cancer
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
This is a randomized, active-controlled, parallel-group, double-blind Phase II trial, of oral restorative microbiota therapy (RMT) or placebo combined with intravenous (IV) durvalumab (MEDI4736) plus chemotherapy in patients with…
- Trial name
- NCT04105270
- Testing
- Oral Restorative Microbiota Therapy (RMT) Capsules, Durvalumab 1500 mg IV, Cisplatin/pemetrexed or Carboplatin/pemetrexed
- Where
- 10 sites in United States
- Volunteers
- 82 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Follicular Lymphoma, Marginal Zone Lymphoma
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
The study follows a Simon's two-stage phase II trial design to evaluate the safety and efficacy of tafasitamab added to rituximab and lenalidomide for two treatment-naïve, parallel, independent cohorts: follicular lymphoma (FL)…
- Trial name
- NCT06792825
- Testing
- Tafasitamab, Rituximab, Lenalidomide
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Smoking Cessation
Rural Smoking Cessation
Understanding ways to help people who live in rural areas quit smoking is a public health priority. quitting smoking among rural people who smoke is a critical public health concern.
- Trial name
- NCT06584929
- Testing
- Nicoderm CQ nicotine patch, Nicorette Nicotine Lozenges
- Where
- United States
- Volunteers
- 544 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
Alcohol-Related Carcinoma, Fanconi Anemia
Role of Acetaldehyde in the Development of Oral Cancer
This is a minimal risk intervention study where healthy volunteers and individuals with Fanconi anemia will consume a single dose of alcohol and provide primarily non-invasive biological samples at various time points.
- Conditions
- Alcohol-Related Carcinoma, Fanconi Anemia, Oral Cavity Carcinoma
- Trial name
- NCT05973656
- Testing
- Alcohol, Biospecimen Collection, Breath Test
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
Completed, with results posted
All 81Smoking, Cigarette
Biomarkers of Exposure and Effect in Standardized Research E-cigarette (SREC) Users
This study is focused on characterizing the toxic and carcinogenic potential of the Standardized Research E-cigarette (SREC) developed by the National Institute on Drug Abuse.
- Trial name
- NCT04003805
- Testing
- Standardized Research E-cigarette (SREC)
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
Smoking
Feasibility of Conducting a Pilot Telehealth Study Assessing the Removal of Filter Ventilation on Smoking Behavior and Biomarkers in Menthol Smokers Switched to Non-menthol Cigarettes
This decentralized clinical trial assesses the feasibility of conducting a tobacco product evaluation study remotely via telehealth visits and mailed samples.
- Trial name
- NCT04514471
- Testing
- Minimally Ventilated non-menthol cigarettes, Ventilated non-menthol cigarettes
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Prostate Cancer
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
This is a phase II clinical trial in patients with metastatic castration sensitive prostate cancer. The objective of the study is to determine the efficacy and further define the safety of the treatment combination.
- Trial name
- NCT03934840
- Testing
- Cabazitaxel, Carboplatin, Abiraterone
- Where
- 8 sites in United States
- Volunteers
- 61 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Tobacco Use
Sugars in Cigarettes
The aim of this study is to investigate the impact of sugar levels in cigarette tobacco on cigarette abuse liability and appeal.
- Trial name
- NCT05308316
- Testing
- Cigarettes with added sucrose
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Leukemia, Myelodysplastic Syndromes
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
This is a single-arm, phase I/II, study of PTCy/sirolimus plus VIC-1911 to prevent GVHD and relapse after Allogeneic Hematopoietic Cell Transplantation (alloHCT).
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Lymphoma
- Trial name
- NCT05120570
- Testing
- VIC- 1911
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota